[The yield of 30-year treasury bonds fell below the 2% mark, and the active bonds of 30-year treasury bonds fell below 2% by 4.26bp, reaching 1.9999% as of press time.On the 13th, silver fell by 1.91%, and the latest main contract positions changed as follows. According to the exchange data, as of December 13th, the main contract silver was 2,502, up or down by -1.91%, with a turnover of 1,004,900 lots. The position data showed that the top 20 seats were net, and the difference position was 30,444 lots. The total turnover of silver futures contracts was 1,505,900 lots, an increase of 417,500 lots over the previous day. The first 20 seats in the contract held 335,600 lots, a decrease of 15,200 lots from the previous day. The short positions in the top 20 seats of the contract were 251,300 lots, an increase of 17,500 lots over the previous day. (Sina Futures)The implementation of personal pension system will bring multiple impacts. According to CCTV news, the implementation of personal pension system will have a far-reaching impact on China's old-age security system. This system aims to improve the multi-level old-age security system, encourage individuals to participate in old-age savings, and improve the level of life security after retirement. In addition, the establishment of individual pension accounts will provide new business growth points for financial institutions and help the development of the capital market. On the whole, this move is expected to promote the transformation of the concept of social pension and promote the sustainable development of the pension service industry.
Organic fluorides in two underground waters in Tochigi Prefecture, Japan exceeded the standard. On the 13th, local time, it was learned that the government department of Tochigi Prefecture in Japan said on the same day that organic fluorides exceeding Japan's provisional safe range were detected in the underground waters of two wells located in Ghost Nuqiu, Zhengang City. (CCTV News)Zuo Qiang served as the chairman and secretary of the Party Committee of China Construction No.1 Bureau (Group) Co., Ltd. On the afternoon of December 13th, China Construction No.1 Bureau (Group) Co., Ltd. held a meeting of cadres and workers. China Construction Group announced the decision to supplement the main leaders of China Construction No.1 Bureau (Group) Co., Ltd.: Comrade Zuo Qiang is the chairman and party secretary of China Construction No.1 Bureau (Group) Co., Ltd.On the 13th, glass fell by 2.14%, and the latest main contract positions changed as follows. According to the exchange data, as of December 13th, the main contract glass closed at 2505, up or down by -2.14%, with a turnover of 671,300 lots. The position data showed that the top 20 seats were clear, and the difference position was 46,081 lots. The total turnover of glass futures contracts was 999,900 lots, an increase of 189,100 lots over the previous day. The first 20 seats in the contract held 565,600 lots, a decrease of 12,000 lots from the previous day. The short positions in the top 20 seats of the contract were 661,500 lots, a decrease of 13,600 lots from the previous day. (Sina Futures)
Asia-Pacific Pharmaceuticals: The new specifications of cefmetazole sodium for injection were approved, and Asia-Pacific Pharmaceuticals announced that the company was approved by National Medical Products Administration, and the new specifications of cefmetazole sodium for injection were 0.5g and 2g, which further enriched the product categories on the basis of the original 1g specifications. The annual sales income of this drug in 2023 was 96.3946 million yuan, accounting for 22.92% of the company's operating income. New specifications are helpful to market promotion and competitiveness improvement, but drug production and sales are affected by policies and market environment, and there are uncertainties.Beizheng 50 rose more than 1%, Huayang Racing Car had a daily limit of 30CM, and Ricky Zhizao, Fuheng New Materials and Bai Xinglong rose more than 10%.Asia-Pacific Pharmaceuticals: The new specifications of cefmetazole sodium for injection were approved, and Asia-Pacific Pharmaceuticals announced that the company was approved by National Medical Products Administration, and the new specifications of cefmetazole sodium for injection were 0.5g and 2g, which further enriched the product categories on the basis of the original 1g specifications. The annual sales income of this drug in 2023 was 96.3946 million yuan, accounting for 22.92% of the company's operating income. New specifications are helpful to market promotion and competitiveness improvement, but drug production and sales are affected by policies and market environment, and there are uncertainties.
Strategy guide
Strategy guide 12-14
Strategy guide
12-14